A new Ohio University study offers a glimmer of hope in the fight against lung cancer. Monica Robins has that story and more ...
For decades, a blood draw in a clinical lab was the only way to quantify your hormones. In 2026, that paradigm is shifting and we are seeing saliva cartridges analyzed by smartphone AI, DNA-based ...
Droves of wellness enthusiasts, biohackers, social-media influencers, and celebrities are injecting experimental “anti-aging” ...
Man of Many on MSN
From Ozempic to BPC-157: Are peptides safe, legal, and worth it?
Peptides are one of the biggest topics in health & fitness right now. Whether the science backs it up depends on which one ...
Women’s health startup Clair has unveiled a wrist-worn wearable that tracks four key reproductive hormones without requiring blood or urine samples. Founded by Stanford graduates Jenny Duan and ...
The Trump administration's new discounted drug platform, TrumpRx, isn't a game-changer for consumers, health care experts said.
Yet in most cases, doctors cannot identify a clear structural cause, making long-term treatment difficult. A new study published in Volume 14 of the journal Bone Research on January 22, 2026, suggests ...
In the past year, I've traveled across continents engaging with thousands of women business owners. From boardrooms to factory floors, small offices to our global summits, I've witnessed a remarkable ...
ST. PETERSBURG, Fla., Jan. 29, 2026 /PRNewswire/ -- Influential Women, a fast growing media platform spotlighting women leaders, founders, and experts across industries, has surpassed 50,000 followers ...
ON AN EARLY December morning in 2004, a panel of advisors to the Food & Drug Administration gathered at a hotel outside of Washington, D.C., to review some data. Pharmaceutical giant Procter & Gamble ...
Generic Protocols for Analytical Validation of Tumor-Informed Circulating Tumor DNA Assays for Molecular Residual Disease: The Blood Profiling Atlas in Cancer's Molecular Residual Disease Analytical ...
Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery This open-label, parallel-group trial randomly assigned 132 participants to receive camizestrant 75, 150, or 300 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results